structurally related to amikacin. It was found to be active against a wide range of pathogenic bacteria, including many gentamicin-resistant strains. The spectrum and degree of activity of UK-18892 were similar to thole of amikacin, and differences were relatively minor. UK-18892 was about twice4s active as amikacin against gentamicin-susceptible strains of Pseudomonas aeruginosa. Both amikacin and UK-18892 were equally active against gentamicin-resistant strains of P. aeruginosa. There were no appreciable differences in the activity of UK-18892 and amikacin against Enterobacteriaceae and Staphylococcus aureus. Crossresistance between these two antimicrobials was also apparent. shown to possess poor antibacterial properties Known-potency antibiotic material was obtained (2), but UK-18892, 1-N-[(S)-4-amino-2-hydrox-from the following sources: UK-18892 from Pfizer Re-VOL. 14, 1978 search, Sandwich, U.K., amikacin from Bristol Laboratories, Slough, U.K., and gentamicin from Roussel Laboratories, London, U.K.
The activity of the three compounds was compared against recent clinical isolates of Pseudomonas aeruginosa, Escherichia coli, Klebsiella spp., indolepositive Proteus spp., Proteus mirabilis, Enterobacter spp., Staphylococcus aureus, and Providencia stuartii. Aminoglycoside-resistant strains of certain species were also tested.
An agar plate dilution technique was used, and Oxoid Isosensitest agar (pH 7.2) was employed throughout. The organ were grown overnight in nutrient broth and then diluted to approximately 106 colony-forming units per ml. A replicating device transferred 1 id to the agar surface. The plates were incubated at 37°C overnight, and the minimum inhibitory concentration (MIC) was defined as that concentration of drug which gave a 99% reduction of the initial count, that is, less than 10 colonies remaining.
The protein binding of gentamicin, amikacin, and UK-18892 was tested in triplicate by an ultrafiltration technique with an Amicon Centriflo cone of 50,000-molecular-weight exclusion. The initial concentration of each drug was 50 lig/ml and was prepared in human UK-18892, AN IN VITRO STUDY 229 serum. The ultrafiltrate was assayed by a large plate diffusion technique, with samples in triplicate applied randomly. The standards were prepared in phosphate-buffered saline made to the same pH as the ultrafiltrate. The 95% confidence limits of the assay were better than ±14%. The ability of UK-18892 and amikacin to be acetylated at the 6'-amino position was studied as in the method descri4ed by Benveniste and Davies (1). An acetylating enzyme was prepared from E. coli R5/W677. Standards of each compound in human serum at 20, 10, 5, 2.5, and 1.25 jg/ml were used.
RESULTS
In Fig. 2 (Fig. 4) , both being about fourfold less active than gentamicin. P. mirabilis (Fig. 5) Fig. 6) tested; they were 16-fold more active than gentamicin, to which all the strains were resistant (MIC > 4 ,ug/ml).
Gentamicin-susceptible strains of S. aureus were susceptible to both the other drugs. Amikacin was slightly more active than the other agents tested.
Two strains of S. aureus which were gentamicin resistant (MIC > 128 ,Lg/ml) were also resistant to UK-18892 (MICs > 128 ,ug/ml), but the MICs of amikacin were 32 and 16,ug/ml.
Both amikacin and UK-18892 were acetylated by the enzyme preparation of R5/W677. In Table 2, the counts per minute obtained from each enzyme preparation are shown.
The protein binding of the three drugs was as follows: gentamicin, 14%; UK-18892, 16.1%; and amikacin, 21.8% bound. DISCUSSION Amikacin is active against many bacteria which are resistant to gentamicin by virtue of the fact that it is enzymatically inactivated at fewer sites than gentamicin (3). However, amikacin can be acetylated at the 6'-amino group. It would appear that UK-18892 has a spectrum of activity similar to that of amikacin and that an enzyme preparation will acetylate both drugs at the 6'-amino group. It is unlikely that the difference in counts obtained with the two drugs is significant. UK-18892 appears to be about twice as active as amikacin against P. aeruginosa, but less difference was noted among those strains resistant to gentamicin. Amikacin and UK-18892 were more active than gentamicin against some of the gentamicin-resistant strains. It seems probable that the majority of these gentamicin-resistant strains are not resistant by virtue of the fact that they possess inactivating enzymes (which would be ineffective against amikacin and UK-18892) but rather because they possess a permeability barrier to all three aminoglycosides. There was little difference between amikacin and UK-18892 in the susceptibility of the other gram-negative organisms tested. Amikacin was no more active than UK-18892 against S. aureus.
Cross-resistance is apparent between amikacin and UK-18892 in the strains of P. aeruginosa and S. aureus tested.
UK-18892, therefore, shares many properties with amikacin. The pharmacology of the two antimicrobial agents would appear to be similar (M. Kendall and R. Wise, manuscript in preparation). 
